MedPath

Synthon Pharmaceuticals, Inc.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.synthon.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

5

FDA:5

Drug Approvals

Levocetirizine dihydrochloride

Approval Date
May 27, 2025
FDA

Tamsulosin hydrochloride

Approval Date
Jan 29, 2024
FDA

Anastrozole

Approval Date
Jan 6, 2011
FDA

Levocetirizine dihydrochloride

Approval Date
Dec 10, 2010
FDA

Bicalutamide

Approval Date
Oct 14, 2010
FDA

Clinical Trials

No trials found

News

Dutch Court Upholds Astellas' Xtandi Formulation Patent Against Synthon Challenge

The District Court of The Hague dismissed Synthon's revocation claim against EP 3 725 778, successfully defending Astellas and Medivation's patent for enzalutamide formulations used in Xtandi for prostate cancer treatment.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.